English

Orexigen Therapeutics, Inc.

EDGAR

OREX Current report (8-K) · filed 2017-12-29

55 filing records in this dataset, filed from 2007-05-25 to 2017-12-29. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

18.9 million USD

2017 Q3 · USD

Exact inputs and evidence

Revenue: 18903000 USD Source

Operating margin

-120.41%

2017 Q3 · %

Exact inputs and evidence

Operating Income: -22762000 USD Source
Revenue: 18903000 USD Source

Operating cash flow

-16.3 million USD

2017 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: -106337000 USD Source
Operating Cash Flow: -90056000 USD Source

Cash and cash equivalents: 45.6 million USD 2017-09-30 Source
Exact value

45577000 USD
Long-term debt including current maturities: 25.4 million USD 2017-09-30 Source
Exact value

25367000 USD
Shares outstanding: 15.6 million shares 2017-09-30 Source
Exact value

15601157 shares

Reported share-count change

6.95% · 1.01 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

14586771 shares · 2016-09-30· Source
15601157 shares · 2017-09-30· Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2017-12-29.

Financial data available through: 2016-12-31.

Coverage by financial measure

Revenue: 10 of 11 periods available· newest 2016-12-31
Operating income: 10 of 11 periods available· newest 2016-12-31
Net income: 10 of 11 periods available· newest 2016-12-31
Operating cash flow: 10 of 11 periods available· newest 2016-12-31
Capital expenditure: 8 of 11 periods available· newest 2016-12-31
Total assets: 10 of 11 periods available· newest 2016-12-31
liabilities: No compatible figures in this window
Current assets: 10 of 11 periods available· newest 2016-12-31
Current liabilities: 10 of 11 periods available· newest 2016-12-31
Cash and cash equivalents: 10 of 11 periods available· newest 2016-12-31
Long-term debt including current maturities: 4 of 11 periods available· newest 2016-12-31
Shares outstanding: 6 of 11 periods available· newest 2016-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+37.8%

Prior period

USD 24.46 million

2015-01-01 – 2015-12-31
Current period

USD 33.71 million

2016-01-01 – 2016-12-31

Exact inputs and evidence

33709000 − 24459000 = 9250000 USD

24459000 USD · 2015-01-01 – 2015-12-31
Inspect prior input Prior source
33709000 USD · 2016-01-01 – 2016-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Orexigen Therapeutics, Inc. · 2016-12-31 Orexigen Therapeutics, Inc. (edgar:1382911) Year-over-year change in Revenue: 9250000 USD Concept: fundies:Revenue Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T14:56:07Z Snapshot: c8844721238a17150f5c7259969a0b0ffd22b7c31ea3be7bd20a59c5a5b16dc5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1382911?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 33709000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1382911/000156459017005547/orex-20161231.xml#175811 Filing: 000156459017005547 Input fundies:Revenue: 24459000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1382911/000156459017005547/orex-20161231.xml#175954 Filing: 000156459017005547
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 44.16 million

Prior period

−USD 68.69 million

2015-01-01 – 2015-12-31
Current period

−USD 24.52 million

2016-01-01 – 2016-12-31

Exact inputs and evidence

-24524000 − -68687000 = 44163000 USD

-68687000 USD · 2015-01-01 – 2015-12-31
Inspect prior input Prior source
-24524000 USD · 2016-01-01 – 2016-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Orexigen Therapeutics, Inc. · 2016-12-31 Orexigen Therapeutics, Inc. (edgar:1382911) Year-over-year change in Net income: 44163000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T14:56:07Z Snapshot: c8844721238a17150f5c7259969a0b0ffd22b7c31ea3be7bd20a59c5a5b16dc5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1382911?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -24524000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1382911/000156459017005547/orex-20161231.xml#182894 Filing: 000156459017005547 Input fundies:NetIncome: -68687000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1382911/000156459017005547/orex-20161231.xml#183048 Filing: 000156459017005547
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 55.24 million

Prior period

−USD 54.47 million

2015-01-01 – 2015-12-31
Current period

−USD 109.71 million

2016-01-01 – 2016-12-31

Exact inputs and evidence

-109713000 − -54473000 = -55240000 USD

-54473000 USD · 2015-01-01 – 2015-12-31
Inspect prior input Prior source
-109713000 USD · 2016-01-01 – 2016-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Orexigen Therapeutics, Inc. · 2016-12-31 Orexigen Therapeutics, Inc. (edgar:1382911) Year-over-year change in Operating cash flow: -55240000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T14:56:07Z Snapshot: c8844721238a17150f5c7259969a0b0ffd22b7c31ea3be7bd20a59c5a5b16dc5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1382911?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -109713000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1382911/000156459017005547/orex-20161231.xml#213633 Filing: 000156459017005547 Input fundies:OperatingCashFlow: -54473000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1382911/000156459017005547/orex-20161231.xml#213886 Filing: 000156459017005547
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-38.7%

Prior period

USD 538,000

2015-01-01 – 2015-12-31
Current period

USD 330,000

2016-01-01 – 2016-12-31

Exact inputs and evidence

330000 − 538000 = -208000 USD

538000 USD · 2015-01-01 – 2015-12-31
Inspect prior input Prior source
330000 USD · 2016-01-01 – 2016-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Orexigen Therapeutics, Inc. · 2016-12-31 Orexigen Therapeutics, Inc. (edgar:1382911) Year-over-year change in Capital expenditure: -208000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T14:56:07Z Snapshot: c8844721238a17150f5c7259969a0b0ffd22b7c31ea3be7bd20a59c5a5b16dc5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1382911?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 330000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1382911/000156459017005547/orex-20161231.xml#216293 Filing: 000156459017005547 Input fundies:CapitalExpenditure: 538000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1382911/000156459017005547/orex-20161231.xml#216502 Filing: 000156459017005547
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2016 2016-01-01 – 2016-12-31

Revenue USD 33.71 million 100% of revenue
Cost of revenue USD 8 million 24% of revenue
Operating expenses USD 82.68 million 245% of revenue
Operating income −USD 56.97 million −169% of revenue
Tax, interest and other Derived −USD 32.45 million −96% of revenue
Net income −USD 24.52 million −73% of revenue

Cash

Operating cash flow −USD 109.71 million −325% of revenue
Capital expenditure USD 330,000 1% of revenue
Free cash flow Derived −USD 110.04 million −326% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2006 Operating loss: operating costs were 32,336% of revenue.
2007 Operating loss: operating costs were 69,216% of revenue.
2008 Operating loss: operating costs were 107,855% of revenue.
2010 Operating loss: operating costs were 4,275% of revenue.
2011 Operating loss: operating costs were 734% of revenue.
2012 Operating loss: operating costs were 2,732% of revenue.
2013 Operating loss: operating costs were 2,352% of revenue.
2014 Operating loss: operating costs were 155% of revenue.
2015 Operating loss: operating costs were 346% of revenue.
2016 Operating loss: operating costs were 269% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2006 2006-01-01 – 2006-12-31	88000	28456000 Derived	-28368000	-864000 Derived	-27504000	-22235000 Derived	Source 2006-01-01 – 2006-12-31: 88000 USD Inspect Revenue Open source 2006-01-01 – 2006-12-31: -28368000 USD Inspect Operating Income Open source 2006-01-01 – 2006-12-31: -27504000 USD Inspect Net Income Open source 2006-01-01 – 2006-12-31: -21808000 USD Inspect Operating Cash Flow Open source 2006-01-01 – 2006-12-31: 427000 USD Inspect Capital Expenditure Open source
2007 2007-01-01 – 2007-12-31	88000	60910000 Derived	-60822000	-3055000 Derived	-57767000	-54922000 Derived	Source 2007-01-01 – 2007-12-31: 88000 USD Inspect Revenue Open source 2007-01-01 – 2007-12-31: -60822000 USD Inspect Operating Income Open source 2007-01-01 – 2007-12-31: -57767000 USD Inspect Net Income Open source 2007-01-01 – 2007-12-31: -54388000 USD Inspect Operating Cash Flow Open source 2007-01-01 – 2007-12-31: 534000 USD Inspect Capital Expenditure Open source
2008 2008-01-01 – 2008-12-31	88000	94912000 Derived	-94824000	-1584000 Derived	-93240000	-76343000 Derived	Source 2008-01-01 – 2008-12-31: 88000 USD Inspect Revenue Open source 2008-01-01 – 2008-12-31: -94824000 USD Inspect Operating Income Open source 2008-01-01 – 2008-12-31: -93240000 USD Inspect Net Income Open source 2008-01-01 – 2008-12-31: -74696000 USD Inspect Operating Cash Flow Open source 2008-01-01 – 2008-12-31: 1647000 USD Inspect Capital Expenditure Open source
2010 2010-01-01 – 2010-12-31	1231000	52626000 Derived	-51395000	520000 Derived	-51915000	5719000 Derived	Source 2010-01-01 – 2010-12-31: 1231000 USD Inspect Revenue Open source 2010-01-01 – 2010-12-31: -51395000 USD Inspect Operating Income Open source 2010-01-01 – 2010-12-31: -51915000 USD Inspect Net Income Open source 2010-01-01 – 2010-12-31: 5764000 USD Inspect Operating Cash Flow Open source 2010-01-01 – 2010-12-31: 45000 USD Inspect Capital Expenditure Open source
2011 2011-01-01 – 2011-12-31	4399000	32282000 Derived	-27883000	175000 Derived	-28058000	Unavailable	Source 2011-01-01 – 2011-12-31: 4399000 USD Inspect Revenue Open source 2011-01-01 – 2011-12-31: -27883000 USD Inspect Operating Income Open source 2011-01-01 – 2011-12-31: -28058000 USD Inspect Net Income Open source 2011-01-01 – 2011-12-31: -29203000 USD Inspect Operating Cash Flow Open source
2012 2012-01-01 – 2012-12-31	3428000	93667000 Derived	-90239000	-145000 Derived	-90094000	Unavailable	Source 2012-01-01 – 2012-12-31: 3428000 USD Inspect Revenue Open source 2012-01-01 – 2012-12-31: -90239000 USD Inspect Operating Income Open source 2012-01-01 – 2012-12-31: -90094000 USD Inspect Net Income Open source 2012-01-01 – 2012-12-31: -68342000 USD Inspect Operating Cash Flow Open source
2013 2013-01-01 – 2013-12-31	3428000	80626000 Derived	-77198000	473000 Derived	-77671000	-71457000 Derived	Source 2013-01-01 – 2013-12-31: 3428000 USD Inspect Revenue Open source 2013-01-01 – 2013-12-31: -77198000 USD Inspect Operating Income Open source 2013-01-01 – 2013-12-31: -77671000 USD Inspect Net Income Open source 2013-01-01 – 2013-12-31: -70817000 USD Inspect Operating Cash Flow Open source 2013-01-01 – 2013-12-31: 640000 USD Inspect Capital Expenditure Open source
2014 2014-01-01 – 2014-12-31	55521000	86051000 Derived	-30530000	6995000 Derived	-37525000	26582000 Derived	Source 2014-01-01 – 2014-12-31: 55521000 USD Inspect Revenue Open source 2014-01-01 – 2014-12-31: -30530000 USD Inspect Operating Income Open source 2014-01-01 – 2014-12-31: -37525000 USD Inspect Net Income Open source 2014-01-01 – 2014-12-31: 26828000 USD Inspect Operating Cash Flow Open source 2014-01-01 – 2014-12-31: 246000 USD Inspect Capital Expenditure Open source
2015 2015-01-01 – 2015-12-31	24459000	84512000 Derived	-60053000	8634000 Derived	-68687000	-55011000 Derived	Source 2015-01-01 – 2015-12-31: 24459000 USD Inspect Revenue Open source 2015-01-01 – 2015-12-31: -60053000 USD Inspect Operating Income Open source 2015-01-01 – 2015-12-31: -68687000 USD Inspect Net Income Open source 2015-01-01 – 2015-12-31: -54473000 USD Inspect Operating Cash Flow Open source 2015-01-01 – 2015-12-31: 538000 USD Inspect Capital Expenditure Open source
2016 2016-01-01 – 2016-12-31	33709000	90679000 Derived	-56970000	-32446000 Derived	-24524000	-110043000 Derived	Source 2016-01-01 – 2016-12-31: 33709000 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -56970000 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -24524000 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: -109713000 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 330000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 33.7M 2016

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20062006-12-31	Revenue	88000	Revenue: 88000 Open source
20072007-12-31	Revenue	88000	Revenue: 88000 Open source
20082008-12-31	Revenue	88000	Revenue: 88000 Open source
20102010-12-31	Revenue	1231000	Revenue: 1231000 Open source
20112011-12-31	Revenue	4399000	Revenue: 4399000 Open source
20122012-12-31	Revenue	3428000	Revenue: 3428000 Open source
20132013-12-31	Revenue	3428000	Revenue: 3428000 Open source
20142014-12-31	Revenue	55521000	Revenue: 55521000 Open source
20152015-12-31	Revenue	24459000	Revenue: 24459000 Open source
20162016-12-31	Revenue	33709000	Revenue: 33709000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

37.8% 2016

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20062006-12-31	Year over year	No prior comparable period	Revenue: 88000 Open source
20072007-12-31	Year over year	0%	Revenue: 88000 Open source Revenue: 88000 Open source
20082008-12-31	Year over year	0%	Revenue: 88000 Open source Revenue: 88000 Open source
20102010-12-31	Year over year	No prior comparable period	Revenue: 1231000 Open source
20112011-12-31	Year over year	257.4%	Revenue: 4399000 Open source Revenue: 1231000 Open source
20122012-12-31	Year over year	-22.1%	Revenue: 3428000 Open source Revenue: 4399000 Open source
20132013-12-31	Year over year	0%	Revenue: 3428000 Open source Revenue: 3428000 Open source
20142014-12-31	Year over year	1,519.6%	Revenue: 55521000 Open source Revenue: 3428000 Open source
20152015-12-31	Year over year	-55.9%	Revenue: 24459000 Open source Revenue: 55521000 Open source
20162016-12-31	Year over year	37.8%	Revenue: 33709000 Open source Revenue: 24459000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -169% 2016

Net margin -72.8% 2016

Free cash flow margin -326.4% 2016

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20062006-12-31	Operating margin	-32,236.4%	Operating Income: -28368000 Open source Revenue: 88000 Open source
20072007-12-31	Operating margin	-69,115.9%	Operating Income: -60822000 Open source Revenue: 88000 Open source
20082008-12-31	Operating margin	-107,754.5%	Operating Income: -94824000 Open source Revenue: 88000 Open source
20102010-12-31	Operating margin	-4,175.1%	Operating Income: -51395000 Open source Revenue: 1231000 Open source
20112011-12-31	Operating margin	-633.8%	Operating Income: -27883000 Open source Revenue: 4399000 Open source
20122012-12-31	Operating margin	-2,632.4%	Operating Income: -90239000 Open source Revenue: 3428000 Open source
20132013-12-31	Operating margin	-2,252%	Operating Income: -77198000 Open source Revenue: 3428000 Open source
20142014-12-31	Operating margin	-55%	Operating Income: -30530000 Open source Revenue: 55521000 Open source
20152015-12-31	Operating margin	-245.5%	Operating Income: -60053000 Open source Revenue: 24459000 Open source
20162016-12-31	Operating margin	-169%	Operating Income: -56970000 Open source Revenue: 33709000 Open source
20062006-12-31	Net margin	-31,254.5%	Net Income: -27504000 Open source Revenue: 88000 Open source
20072007-12-31	Net margin	-65,644.3%	Net Income: -57767000 Open source Revenue: 88000 Open source
20082008-12-31	Net margin	-105,954.5%	Net Income: -93240000 Open source Revenue: 88000 Open source
20102010-12-31	Net margin	-4,217.3%	Net Income: -51915000 Open source Revenue: 1231000 Open source
20112011-12-31	Net margin	-637.8%	Net Income: -28058000 Open source Revenue: 4399000 Open source
20122012-12-31	Net margin	-2,628.2%	Net Income: -90094000 Open source Revenue: 3428000 Open source
20132013-12-31	Net margin	-2,265.8%	Net Income: -77671000 Open source Revenue: 3428000 Open source
20142014-12-31	Net margin	-67.6%	Net Income: -37525000 Open source Revenue: 55521000 Open source
20152015-12-31	Net margin	-280.8%	Net Income: -68687000 Open source Revenue: 24459000 Open source
20162016-12-31	Net margin	-72.8%	Net Income: -24524000 Open source Revenue: 33709000 Open source
20062006-12-31	Free cash flow margin	-25,267%	Revenue: 88000 Open source Operating Cash Flow: -21808000 Open source Capital Expenditure: 427000 Open source
20072007-12-31	Free cash flow margin	-62,411.4%	Revenue: 88000 Open source Operating Cash Flow: -54388000 Open source Capital Expenditure: 534000 Open source
20082008-12-31	Free cash flow margin	-86,753.4%	Revenue: 88000 Open source Operating Cash Flow: -74696000 Open source Capital Expenditure: 1647000 Open source
20102010-12-31	Free cash flow margin	464.6%	Revenue: 1231000 Open source Operating Cash Flow: 5764000 Open source Capital Expenditure: 45000 Open source
20112011-12-31	Free cash flow margin	Not reported	Revenue: 4399000 Open source Operating Cash Flow: -29203000 Open source
20122012-12-31	Free cash flow margin	Not reported	Revenue: 3428000 Open source Operating Cash Flow: -68342000 Open source
20132013-12-31	Free cash flow margin	-2,084.5%	Revenue: 3428000 Open source Operating Cash Flow: -70817000 Open source Capital Expenditure: 640000 Open source
20142014-12-31	Free cash flow margin	47.9%	Revenue: 55521000 Open source Operating Cash Flow: 26828000 Open source Capital Expenditure: 246000 Open source
20152015-12-31	Free cash flow margin	-224.9%	Revenue: 24459000 Open source Operating Cash Flow: -54473000 Open source Capital Expenditure: 538000 Open source
20162016-12-31	Free cash flow margin	-326.4%	Revenue: 33709000 Open source Operating Cash Flow: -109713000 Open source Capital Expenditure: 330000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -109.7M 2016

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20062006-12-31	Operating cash flow	-21808000	Operating Cash Flow: -21808000 Open source
20072007-12-31	Operating cash flow	-54388000	Operating Cash Flow: -54388000 Open source
20082008-12-31	Operating cash flow	-74696000	Operating Cash Flow: -74696000 Open source
20102010-12-31	Operating cash flow	5764000	Operating Cash Flow: 5764000 Open source
20112011-12-31	Operating cash flow	-29203000	Operating Cash Flow: -29203000 Open source
20122012-12-31	Operating cash flow	-68342000	Operating Cash Flow: -68342000 Open source
20132013-12-31	Operating cash flow	-70817000	Operating Cash Flow: -70817000 Open source
20142014-12-31	Operating cash flow	26828000	Operating Cash Flow: 26828000 Open source
20152015-12-31	Operating cash flow	-54473000	Operating Cash Flow: -54473000 Open source
20162016-12-31	Operating cash flow	-109713000	Operating Cash Flow: -109713000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -110M 2016

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20062006-12-31	Free cash flow	-22235000	Operating Cash Flow: -21808000 Open source Capital Expenditure: 427000 Open source
20072007-12-31	Free cash flow	-54922000	Operating Cash Flow: -54388000 Open source Capital Expenditure: 534000 Open source
20082008-12-31	Free cash flow	-76343000	Operating Cash Flow: -74696000 Open source Capital Expenditure: 1647000 Open source
20102010-12-31	Free cash flow	5719000	Operating Cash Flow: 5764000 Open source Capital Expenditure: 45000 Open source
20112011-12-31	Free cash flow	Unavailable	Operating Cash Flow: -29203000 Open source
20122012-12-31	Free cash flow	Unavailable	Operating Cash Flow: -68342000 Open source
20132013-12-31	Free cash flow	-71457000	Operating Cash Flow: -70817000 Open source Capital Expenditure: 640000 Open source
20142014-12-31	Free cash flow	26582000	Operating Cash Flow: 26828000 Open source Capital Expenditure: 246000 Open source
20152015-12-31	Free cash flow	-55011000	Operating Cash Flow: -54473000 Open source Capital Expenditure: 538000 Open source
20162016-12-31	Free cash flow	-110043000	Operating Cash Flow: -109713000 Open source Capital Expenditure: 330000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

Not enough comparable data to show this history.

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2006-12-31	Liabilities / assets	Not reported	Total Assets: 36810000 Open source
2007-12-31	Liabilities / assets	Not reported	Total Assets: 91320000 Open source
2008-12-31	Liabilities / assets	Not reported	Total Assets: 91908000 Open source
2010-12-31	Liabilities / assets	Not reported	No source recorded
2011-12-31	Liabilities / assets	Not reported	Total Assets: 149700000 Open source
2012-12-31	Liabilities / assets	Not reported	Total Assets: 139154000 Open source
2013-12-31	Liabilities / assets	Not reported	Total Assets: 180121000 Open source
2014-12-31	Liabilities / assets	Not reported	Total Assets: 212981000 Open source
2015-12-31	Liabilities / assets	Not reported	Total Assets: 236330000 Open source
2016-12-31	Liabilities / assets	Not reported	Total Assets: 304589000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

3.43× 2016

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20062006-12-31	Current assets / current liabilities	6.94×	Current Assets: 34635000 Open source Current Liabilities: 4991000 Open source
20072007-12-31	Current assets / current liabilities	6.62×	Current Assets: 87925000 Open source Current Liabilities: 13277000 Open source
20082008-12-31	Current assets / current liabilities	3.3×	Current Assets: 87351000 Open source Current Liabilities: 26489000 Open source
2010-12-31	Current assets / current liabilities	Not reported	No source recorded
20112011-12-31	Current assets / current liabilities	19.3×	Current Assets: 148719000 Open source Current Liabilities: 7706000 Open source
20122012-12-31	Current assets / current liabilities	5.53×	Current Assets: 138894000 Open source Current Liabilities: 25114000 Open source
20132013-12-31	Current assets / current liabilities	7.8×	Current Assets: 178282000 Open source Current Liabilities: 22853000 Open source
20142014-12-31	Current assets / current liabilities	7.11×	Current Assets: 211326000 Open source Current Liabilities: 29714000 Open source
20152015-12-31	Current assets / current liabilities	7.25×	Current Assets: 233895000 Open source Current Liabilities: 32241000 Open source
20162016-12-31	Current assets / current liabilities	3.43×	Current Assets: 224461000 Open source Current Liabilities: 65360000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2006 2006-01-01 – 2006-12-31	−USD 27.5 million Exact value Exact value: -27504000 USD 2006-01-01 – 2006-12-31: -27504000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Orexigen Therapeutics, Inc. · 2006-12-31 Orexigen Therapeutics, Inc. (edgar:1382911) Net Income: -27504000 USD Concept: fundies:NetIncome Period: 2006-01-01 to 2006-12-31 Values: Latest reported Published: 2026-11-02T14:56:07Z Snapshot: c8844721238a17150f5c7259969a0b0ffd22b7c31ea3be7bd20a59c5a5b16dc5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1382911/explain?concept=fundies%3ANetIncome&period=2006-12-31&surface=latest&period_type=duration&start=2006-01-01&unit=USD&dimensions= Input fundies:NetIncome: -27504000 USD (2006-01-01 to 2006-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1382911/0001193125-09-053916.txt#9840 The citation records this snapshot. The page link may show a newer release later.	−USD 21.81 million Exact value Exact value: -21808000 USD 2006-01-01 – 2006-12-31: -21808000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Orexigen Therapeutics, Inc. · 2006-12-31 Orexigen Therapeutics, Inc. (edgar:1382911) Operating Cash Flow: -21808000 USD Concept: fundies:OperatingCashFlow Period: 2006-01-01 to 2006-12-31 Values: Latest reported Published: 2026-11-02T14:56:07Z Snapshot: c8844721238a17150f5c7259969a0b0ffd22b7c31ea3be7bd20a59c5a5b16dc5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1382911/explain?concept=fundies%3AOperatingCashFlow&period=2006-12-31&surface=latest&period_type=duration&start=2006-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -21808000 USD (2006-01-01 to 2006-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1382911/0001193125-09-053916.txt#10110 The citation records this snapshot. The page link may show a newer release later.	USD 427,000 Exact value Exact value: 427000 USD 2006-01-01 – 2006-12-31: 427000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Orexigen Therapeutics, Inc. · 2006-12-31 Orexigen Therapeutics, Inc. (edgar:1382911) Capital Expenditure: 427000 USD Concept: fundies:CapitalExpenditure Period: 2006-01-01 to 2006-12-31 Values: Latest reported Published: 2026-11-02T14:56:07Z Snapshot: c8844721238a17150f5c7259969a0b0ffd22b7c31ea3be7bd20a59c5a5b16dc5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1382911/explain?concept=fundies%3ACapitalExpenditure&period=2006-12-31&surface=latest&period_type=duration&start=2006-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 427000 USD (2006-01-01 to 2006-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1382911/0001193125-09-053916.txt#10182 The citation records this snapshot. The page link may show a newer release later.	−USD 22.24 million Calculation and evidence -21808000 − 427000 USD Exact free cash flow: -22235000 USD 2006-01-01 – 2006-12-31: -21808000 USD · Inspect Operating Cash Flow · Source 2006-01-01 – 2006-12-31: 427000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Orexigen Therapeutics, Inc. · 2006-12-31 Orexigen Therapeutics, Inc. (edgar:1382911) Free cash flow: -22235000 USD Concept: free-cash-flow Period: 2006-01-01 to 2006-12-31 Values: Latest reported Published: 2026-11-02T14:56:07Z Snapshot: c8844721238a17150f5c7259969a0b0ffd22b7c31ea3be7bd20a59c5a5b16dc5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1382911?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -21808000 USD (2006-01-01 to 2006-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1382911/0001193125-09-053916.txt#10110 Input fundies:CapitalExpenditure: 427000 USD (2006-01-01 to 2006-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1382911/0001193125-09-053916.txt#10182 The citation records this snapshot. The page link may show a newer release later.
2007 2007-01-01 – 2007-12-31	−USD 57.77 million Exact value Exact value: -57767000 USD 2007-01-01 – 2007-12-31: -57767000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Orexigen Therapeutics, Inc. · 2007-12-31 Orexigen Therapeutics, Inc. (edgar:1382911) Net Income: -57767000 USD Concept: fundies:NetIncome Period: 2007-01-01 to 2007-12-31 Values: Latest reported Published: 2026-11-02T14:56:07Z Snapshot: c8844721238a17150f5c7259969a0b0ffd22b7c31ea3be7bd20a59c5a5b16dc5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1382911/explain?concept=fundies%3ANetIncome&period=2007-12-31&surface=latest&period_type=duration&start=2007-01-01&unit=USD&dimensions= Input fundies:NetIncome: -57767000 USD (2007-01-01 to 2007-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1382911/0001193125-10-053927.txt#10393 The citation records this snapshot. The page link may show a newer release later.	−USD 54.39 million Exact value Exact value: -54388000 USD 2007-01-01 – 2007-12-31: -54388000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Orexigen Therapeutics, Inc. · 2007-12-31 Orexigen Therapeutics, Inc. (edgar:1382911) Operating Cash Flow: -54388000 USD Concept: fundies:OperatingCashFlow Period: 2007-01-01 to 2007-12-31 Values: Latest reported Published: 2026-11-02T14:56:07Z Snapshot: c8844721238a17150f5c7259969a0b0ffd22b7c31ea3be7bd20a59c5a5b16dc5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1382911/explain?concept=fundies%3AOperatingCashFlow&period=2007-12-31&surface=latest&period_type=duration&start=2007-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -54388000 USD (2007-01-01 to 2007-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1382911/0001193125-10-053927.txt#10681 The citation records this snapshot. The page link may show a newer release later.	USD 534,000 Exact value Exact value: 534000 USD 2007-01-01 – 2007-12-31: 534000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Orexigen Therapeutics, Inc. · 2007-12-31 Orexigen Therapeutics, Inc. (edgar:1382911) Capital Expenditure: 534000 USD Concept: fundies:CapitalExpenditure Period: 2007-01-01 to 2007-12-31 Values: Latest reported Published: 2026-11-02T14:56:07Z Snapshot: c8844721238a17150f5c7259969a0b0ffd22b7c31ea3be7bd20a59c5a5b16dc5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1382911/explain?concept=fundies%3ACapitalExpenditure&period=2007-12-31&surface=latest&period_type=duration&start=2007-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 534000 USD (2007-01-01 to 2007-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1382911/0001193125-10-053927.txt#10753 The citation records this snapshot. The page link may show a newer release later.	−USD 54.92 million Calculation and evidence -54388000 − 534000 USD Exact free cash flow: -54922000 USD 2007-01-01 – 2007-12-31: -54388000 USD · Inspect Operating Cash Flow · Source 2007-01-01 – 2007-12-31: 534000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Orexigen Therapeutics, Inc. · 2007-12-31 Orexigen Therapeutics, Inc. (edgar:1382911) Free cash flow: -54922000 USD Concept: free-cash-flow Period: 2007-01-01 to 2007-12-31 Values: Latest reported Published: 2026-11-02T14:56:07Z Snapshot: c8844721238a17150f5c7259969a0b0ffd22b7c31ea3be7bd20a59c5a5b16dc5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1382911?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -54388000 USD (2007-01-01 to 2007-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1382911/0001193125-10-053927.txt#10681 Input fundies:CapitalExpenditure: 534000 USD (2007-01-01 to 2007-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1382911/0001193125-10-053927.txt#10753 The citation records this snapshot. The page link may show a newer release later.
2008 2008-01-01 – 2008-12-31	−USD 93.24 million Exact value Exact value: -93240000 USD 2008-01-01 – 2008-12-31: -93240000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Orexigen Therapeutics, Inc. · 2008-12-31 Orexigen Therapeutics, Inc. (edgar:1382911) Net Income: -93240000 USD Concept: fundies:NetIncome Period: 2008-01-01 to 2008-12-31 Values: Latest reported Published: 2026-11-02T14:56:07Z Snapshot: c8844721238a17150f5c7259969a0b0ffd22b7c31ea3be7bd20a59c5a5b16dc5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1382911/explain?concept=fundies%3ANetIncome&period=2008-12-31&surface=latest&period_type=duration&start=2008-01-01&unit=USD&dimensions= Input fundies:NetIncome: -93240000 USD (2008-01-01 to 2008-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1382911/0001193125-11-063548.txt#7743 The citation records this snapshot. The page link may show a newer release later.	−USD 74.7 million Exact value Exact value: -74696000 USD 2008-01-01 – 2008-12-31: -74696000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Orexigen Therapeutics, Inc. · 2008-12-31 Orexigen Therapeutics, Inc. (edgar:1382911) Operating Cash Flow: -74696000 USD Concept: fundies:OperatingCashFlow Period: 2008-01-01 to 2008-12-31 Values: Latest reported Published: 2026-11-02T14:56:07Z Snapshot: c8844721238a17150f5c7259969a0b0ffd22b7c31ea3be7bd20a59c5a5b16dc5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1382911/explain?concept=fundies%3AOperatingCashFlow&period=2008-12-31&surface=latest&period_type=duration&start=2008-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -74696000 USD (2008-01-01 to 2008-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1382911/0001193125-11-063548.txt#7953 The citation records this snapshot. The page link may show a newer release later.	USD 1.65 million Exact value Exact value: 1647000 USD 2008-01-01 – 2008-12-31: 1647000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Orexigen Therapeutics, Inc. · 2008-12-31 Orexigen Therapeutics, Inc. (edgar:1382911) Capital Expenditure: 1647000 USD Concept: fundies:CapitalExpenditure Period: 2008-01-01 to 2008-12-31 Values: Latest reported Published: 2026-11-02T14:56:07Z Snapshot: c8844721238a17150f5c7259969a0b0ffd22b7c31ea3be7bd20a59c5a5b16dc5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1382911/explain?concept=fundies%3ACapitalExpenditure&period=2008-12-31&surface=latest&period_type=duration&start=2008-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1647000 USD (2008-01-01 to 2008-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1382911/0001193125-11-063548.txt#8009 The citation records this snapshot. The page link may show a newer release later.	−USD 76.34 million Calculation and evidence -74696000 − 1647000 USD Exact free cash flow: -76343000 USD 2008-01-01 – 2008-12-31: -74696000 USD · Inspect Operating Cash Flow · Source 2008-01-01 – 2008-12-31: 1647000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Orexigen Therapeutics, Inc. · 2008-12-31 Orexigen Therapeutics, Inc. (edgar:1382911) Free cash flow: -76343000 USD Concept: free-cash-flow Period: 2008-01-01 to 2008-12-31 Values: Latest reported Published: 2026-11-02T14:56:07Z Snapshot: c8844721238a17150f5c7259969a0b0ffd22b7c31ea3be7bd20a59c5a5b16dc5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1382911?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -74696000 USD (2008-01-01 to 2008-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1382911/0001193125-11-063548.txt#7953 Input fundies:CapitalExpenditure: 1647000 USD (2008-01-01 to 2008-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1382911/0001193125-11-063548.txt#8009 The citation records this snapshot. The page link may show a newer release later.
2010 2010-01-01 – 2010-12-31	−USD 51.92 million Exact value Exact value: -51915000 USD 2010-01-01 – 2010-12-31: -51915000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Orexigen Therapeutics, Inc. · 2010-12-31 Orexigen Therapeutics, Inc. (edgar:1382911) Net Income: -51915000 USD Concept: fundies:NetIncome Period: 2010-01-01 to 2010-12-31 Values: Latest reported Published: 2026-11-02T14:56:07Z Snapshot: c8844721238a17150f5c7259969a0b0ffd22b7c31ea3be7bd20a59c5a5b16dc5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1382911/explain?concept=fundies%3ANetIncome&period=2010-12-31&surface=latest&period_type=duration&start=2010-01-01&unit=USD&dimensions= Input fundies:NetIncome: -51915000 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1382911/000119312513107746/orex-20121231.xml#97144 Filing: 000119312513107746 The citation records this snapshot. The page link may show a newer release later.	USD 5.76 million Exact value Exact value: 5764000 USD 2010-01-01 – 2010-12-31: 5764000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Orexigen Therapeutics, Inc. · 2010-12-31 Orexigen Therapeutics, Inc. (edgar:1382911) Operating Cash Flow: 5764000 USD Concept: fundies:OperatingCashFlow Period: 2010-01-01 to 2010-12-31 Values: Latest reported Published: 2026-11-02T14:56:07Z Snapshot: c8844721238a17150f5c7259969a0b0ffd22b7c31ea3be7bd20a59c5a5b16dc5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1382911/explain?concept=fundies%3AOperatingCashFlow&period=2010-12-31&surface=latest&period_type=duration&start=2010-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 5764000 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1382911/000119312513107746/orex-20121231.xml#88619 Filing: 000119312513107746 The citation records this snapshot. The page link may show a newer release later.	USD 45,000 Exact value Exact value: 45000 USD 2010-01-01 – 2010-12-31: 45000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Orexigen Therapeutics, Inc. · 2010-12-31 Orexigen Therapeutics, Inc. (edgar:1382911) Capital Expenditure: 45000 USD Concept: fundies:CapitalExpenditure Period: 2010-01-01 to 2010-12-31 Values: Latest reported Published: 2026-11-02T14:56:07Z Snapshot: c8844721238a17150f5c7259969a0b0ffd22b7c31ea3be7bd20a59c5a5b16dc5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1382911/explain?concept=fundies%3ACapitalExpenditure&period=2010-12-31&surface=latest&period_type=duration&start=2010-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 45000 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1382911/000119312513107746/orex-20121231.xml#90272 Filing: 000119312513107746 The citation records this snapshot. The page link may show a newer release later.	USD 5.72 million Calculation and evidence 5764000 − 45000 USD Exact free cash flow: 5719000 USD 2010-01-01 – 2010-12-31: 5764000 USD · Inspect Operating Cash Flow · Source 2010-01-01 – 2010-12-31: 45000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Orexigen Therapeutics, Inc. · 2010-12-31 Orexigen Therapeutics, Inc. (edgar:1382911) Free cash flow: 5719000 USD Concept: free-cash-flow Period: 2010-01-01 to 2010-12-31 Values: Latest reported Published: 2026-11-02T14:56:07Z Snapshot: c8844721238a17150f5c7259969a0b0ffd22b7c31ea3be7bd20a59c5a5b16dc5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1382911?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 5764000 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1382911/000119312513107746/orex-20121231.xml#88619 Filing: 000119312513107746 Input fundies:CapitalExpenditure: 45000 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1382911/000119312513107746/orex-20121231.xml#90272 Filing: 000119312513107746 The citation records this snapshot. The page link may show a newer release later.
2011 2011-01-01 – 2011-12-31	−USD 28.06 million Exact value Exact value: -28058000 USD 2011-01-01 – 2011-12-31: -28058000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Orexigen Therapeutics, Inc. · 2011-12-31 Orexigen Therapeutics, Inc. (edgar:1382911) Net Income: -28058000 USD Concept: fundies:NetIncome Period: 2011-01-01 to 2011-12-31 Values: Latest reported Published: 2026-11-02T14:56:07Z Snapshot: c8844721238a17150f5c7259969a0b0ffd22b7c31ea3be7bd20a59c5a5b16dc5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1382911/explain?concept=fundies%3ANetIncome&period=2011-12-31&surface=latest&period_type=duration&start=2011-01-01&unit=USD&dimensions= Input fundies:NetIncome: -28058000 USD (2011-01-01 to 2011-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1382911/000119312514097515/orex-20131231.xml#94639 Filing: 000119312514097515 The citation records this snapshot. The page link may show a newer release later.	−USD 29.2 million Exact value Exact value: -29203000 USD 2011-01-01 – 2011-12-31: -29203000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Orexigen Therapeutics, Inc. · 2011-12-31 Orexigen Therapeutics, Inc. (edgar:1382911) Operating Cash Flow: -29203000 USD Concept: fundies:OperatingCashFlow Period: 2011-01-01 to 2011-12-31 Values: Latest reported Published: 2026-11-02T14:56:07Z Snapshot: c8844721238a17150f5c7259969a0b0ffd22b7c31ea3be7bd20a59c5a5b16dc5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1382911/explain?concept=fundies%3AOperatingCashFlow&period=2011-12-31&surface=latest&period_type=duration&start=2011-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -29203000 USD (2011-01-01 to 2011-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1382911/000119312514097515/orex-20131231.xml#86626 Filing: 000119312514097515 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2012 2012-01-01 – 2012-12-31	−USD 90.09 million Exact value Exact value: -90094000 USD 2012-01-01 – 2012-12-31: -90094000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Orexigen Therapeutics, Inc. · 2012-12-31 Orexigen Therapeutics, Inc. (edgar:1382911) Net Income: -90094000 USD Concept: fundies:NetIncome Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T14:56:07Z Snapshot: c8844721238a17150f5c7259969a0b0ffd22b7c31ea3be7bd20a59c5a5b16dc5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1382911/explain?concept=fundies%3ANetIncome&period=2012-12-31&surface=latest&period_type=duration&start=2012-01-01&unit=USD&dimensions= Input fundies:NetIncome: -90094000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1382911/000119312515069192/orex-20141231.xml#948997 Filing: 000119312515069192 The citation records this snapshot. The page link may show a newer release later.	−USD 68.34 million Exact value Exact value: -68342000 USD 2012-01-01 – 2012-12-31: -68342000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Orexigen Therapeutics, Inc. · 2012-12-31 Orexigen Therapeutics, Inc. (edgar:1382911) Operating Cash Flow: -68342000 USD Concept: fundies:OperatingCashFlow Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T14:56:07Z Snapshot: c8844721238a17150f5c7259969a0b0ffd22b7c31ea3be7bd20a59c5a5b16dc5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1382911/explain?concept=fundies%3AOperatingCashFlow&period=2012-12-31&surface=latest&period_type=duration&start=2012-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -68342000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1382911/000119312515069192/orex-20141231.xml#940677 Filing: 000119312515069192 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2013 2013-01-01 – 2013-12-31	−USD 77.67 million Exact value Exact value: -77671000 USD 2013-01-01 – 2013-12-31: -77671000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Orexigen Therapeutics, Inc. · 2013-12-31 Orexigen Therapeutics, Inc. (edgar:1382911) Net Income: -77671000 USD Concept: fundies:NetIncome Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T14:56:07Z Snapshot: c8844721238a17150f5c7259969a0b0ffd22b7c31ea3be7bd20a59c5a5b16dc5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1382911/explain?concept=fundies%3ANetIncome&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:NetIncome: -77671000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1382911/000119312516481707/orex-20151231.xml#113543 Filing: 000119312516481707 The citation records this snapshot. The page link may show a newer release later.	−USD 70.82 million Exact value Exact value: -70817000 USD 2013-01-01 – 2013-12-31: -70817000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Orexigen Therapeutics, Inc. · 2013-12-31 Orexigen Therapeutics, Inc. (edgar:1382911) Operating Cash Flow: -70817000 USD Concept: fundies:OperatingCashFlow Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T14:56:07Z Snapshot: c8844721238a17150f5c7259969a0b0ffd22b7c31ea3be7bd20a59c5a5b16dc5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1382911/explain?concept=fundies%3AOperatingCashFlow&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -70817000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1382911/000119312516481707/orex-20151231.xml#104836 Filing: 000119312516481707 The citation records this snapshot. The page link may show a newer release later.	USD 640,000 Exact value Exact value: 640000 USD 2013-01-01 – 2013-12-31: 640000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Orexigen Therapeutics, Inc. · 2013-12-31 Orexigen Therapeutics, Inc. (edgar:1382911) Capital Expenditure: 640000 USD Concept: fundies:CapitalExpenditure Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T14:56:07Z Snapshot: c8844721238a17150f5c7259969a0b0ffd22b7c31ea3be7bd20a59c5a5b16dc5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1382911/explain?concept=fundies%3ACapitalExpenditure&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 640000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1382911/000119312516481707/orex-20151231.xml#109358 Filing: 000119312516481707 The citation records this snapshot. The page link may show a newer release later.	−USD 71.46 million Calculation and evidence -70817000 − 640000 USD Exact free cash flow: -71457000 USD 2013-01-01 – 2013-12-31: -70817000 USD · Inspect Operating Cash Flow · Source 2013-01-01 – 2013-12-31: 640000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Orexigen Therapeutics, Inc. · 2013-12-31 Orexigen Therapeutics, Inc. (edgar:1382911) Free cash flow: -71457000 USD Concept: free-cash-flow Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T14:56:07Z Snapshot: c8844721238a17150f5c7259969a0b0ffd22b7c31ea3be7bd20a59c5a5b16dc5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1382911?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -70817000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1382911/000119312516481707/orex-20151231.xml#104836 Filing: 000119312516481707 Input fundies:CapitalExpenditure: 640000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1382911/000119312516481707/orex-20151231.xml#109358 Filing: 000119312516481707 The citation records this snapshot. The page link may show a newer release later.
2014 2014-01-01 – 2014-12-31	−USD 37.53 million Exact value Exact value: -37525000 USD 2014-01-01 – 2014-12-31: -37525000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Orexigen Therapeutics, Inc. · 2014-12-31 Orexigen Therapeutics, Inc. (edgar:1382911) Net Income: -37525000 USD Concept: fundies:NetIncome Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T14:56:07Z Snapshot: c8844721238a17150f5c7259969a0b0ffd22b7c31ea3be7bd20a59c5a5b16dc5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1382911/explain?concept=fundies%3ANetIncome&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:NetIncome: -37525000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1382911/000156459017005547/orex-20161231.xml#183202 Filing: 000156459017005547 The citation records this snapshot. The page link may show a newer release later.	USD 26.83 million Exact value Exact value: 26828000 USD 2014-01-01 – 2014-12-31: 26828000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Orexigen Therapeutics, Inc. · 2014-12-31 Orexigen Therapeutics, Inc. (edgar:1382911) Operating Cash Flow: 26828000 USD Concept: fundies:OperatingCashFlow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T14:56:07Z Snapshot: c8844721238a17150f5c7259969a0b0ffd22b7c31ea3be7bd20a59c5a5b16dc5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1382911/explain?concept=fundies%3AOperatingCashFlow&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 26828000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1382911/000156459017005547/orex-20161231.xml#214138 Filing: 000156459017005547 The citation records this snapshot. The page link may show a newer release later.	USD 246,000 Exact value Exact value: 246000 USD 2014-01-01 – 2014-12-31: 246000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Orexigen Therapeutics, Inc. · 2014-12-31 Orexigen Therapeutics, Inc. (edgar:1382911) Capital Expenditure: 246000 USD Concept: fundies:CapitalExpenditure Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T14:56:07Z Snapshot: c8844721238a17150f5c7259969a0b0ffd22b7c31ea3be7bd20a59c5a5b16dc5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1382911/explain?concept=fundies%3ACapitalExpenditure&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 246000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1382911/000156459017005547/orex-20161231.xml#216711 Filing: 000156459017005547 The citation records this snapshot. The page link may show a newer release later.	USD 26.58 million Calculation and evidence 26828000 − 246000 USD Exact free cash flow: 26582000 USD 2014-01-01 – 2014-12-31: 26828000 USD · Inspect Operating Cash Flow · Source 2014-01-01 – 2014-12-31: 246000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Orexigen Therapeutics, Inc. · 2014-12-31 Orexigen Therapeutics, Inc. (edgar:1382911) Free cash flow: 26582000 USD Concept: free-cash-flow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T14:56:07Z Snapshot: c8844721238a17150f5c7259969a0b0ffd22b7c31ea3be7bd20a59c5a5b16dc5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1382911?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 26828000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1382911/000156459017005547/orex-20161231.xml#214138 Filing: 000156459017005547 Input fundies:CapitalExpenditure: 246000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1382911/000156459017005547/orex-20161231.xml#216711 Filing: 000156459017005547 The citation records this snapshot. The page link may show a newer release later.
2015 2015-01-01 – 2015-12-31	−USD 68.69 million Exact value Exact value: -68687000 USD 2015-01-01 – 2015-12-31: -68687000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Orexigen Therapeutics, Inc. · 2015-12-31 Orexigen Therapeutics, Inc. (edgar:1382911) Net Income: -68687000 USD Concept: fundies:NetIncome Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T14:56:07Z Snapshot: c8844721238a17150f5c7259969a0b0ffd22b7c31ea3be7bd20a59c5a5b16dc5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1382911/explain?concept=fundies%3ANetIncome&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:NetIncome: -68687000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1382911/000156459017005547/orex-20161231.xml#183048 Filing: 000156459017005547 The citation records this snapshot. The page link may show a newer release later.	−USD 54.47 million Exact value Exact value: -54473000 USD 2015-01-01 – 2015-12-31: -54473000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Orexigen Therapeutics, Inc. · 2015-12-31 Orexigen Therapeutics, Inc. (edgar:1382911) Operating Cash Flow: -54473000 USD Concept: fundies:OperatingCashFlow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T14:56:07Z Snapshot: c8844721238a17150f5c7259969a0b0ffd22b7c31ea3be7bd20a59c5a5b16dc5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1382911/explain?concept=fundies%3AOperatingCashFlow&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -54473000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1382911/000156459017005547/orex-20161231.xml#213886 Filing: 000156459017005547 The citation records this snapshot. The page link may show a newer release later.	USD 538,000 Exact value Exact value: 538000 USD 2015-01-01 – 2015-12-31: 538000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Orexigen Therapeutics, Inc. · 2015-12-31 Orexigen Therapeutics, Inc. (edgar:1382911) Capital Expenditure: 538000 USD Concept: fundies:CapitalExpenditure Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T14:56:07Z Snapshot: c8844721238a17150f5c7259969a0b0ffd22b7c31ea3be7bd20a59c5a5b16dc5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1382911/explain?concept=fundies%3ACapitalExpenditure&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 538000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1382911/000156459017005547/orex-20161231.xml#216502 Filing: 000156459017005547 The citation records this snapshot. The page link may show a newer release later.	−USD 55.01 million Calculation and evidence -54473000 − 538000 USD Exact free cash flow: -55011000 USD 2015-01-01 – 2015-12-31: -54473000 USD · Inspect Operating Cash Flow · Source 2015-01-01 – 2015-12-31: 538000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Orexigen Therapeutics, Inc. · 2015-12-31 Orexigen Therapeutics, Inc. (edgar:1382911) Free cash flow: -55011000 USD Concept: free-cash-flow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T14:56:07Z Snapshot: c8844721238a17150f5c7259969a0b0ffd22b7c31ea3be7bd20a59c5a5b16dc5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1382911?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -54473000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1382911/000156459017005547/orex-20161231.xml#213886 Filing: 000156459017005547 Input fundies:CapitalExpenditure: 538000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1382911/000156459017005547/orex-20161231.xml#216502 Filing: 000156459017005547 The citation records this snapshot. The page link may show a newer release later.
2016 2016-01-01 – 2016-12-31	−USD 24.52 million Exact value Exact value: -24524000 USD 2016-01-01 – 2016-12-31: -24524000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Orexigen Therapeutics, Inc. · 2016-12-31 Orexigen Therapeutics, Inc. (edgar:1382911) Net Income: -24524000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T14:56:07Z Snapshot: c8844721238a17150f5c7259969a0b0ffd22b7c31ea3be7bd20a59c5a5b16dc5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1382911/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -24524000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1382911/000156459017005547/orex-20161231.xml#182894 Filing: 000156459017005547 The citation records this snapshot. The page link may show a newer release later.	−USD 109.71 million Exact value Exact value: -109713000 USD 2016-01-01 – 2016-12-31: -109713000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Orexigen Therapeutics, Inc. · 2016-12-31 Orexigen Therapeutics, Inc. (edgar:1382911) Operating Cash Flow: -109713000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T14:56:07Z Snapshot: c8844721238a17150f5c7259969a0b0ffd22b7c31ea3be7bd20a59c5a5b16dc5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1382911/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -109713000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1382911/000156459017005547/orex-20161231.xml#213633 Filing: 000156459017005547 The citation records this snapshot. The page link may show a newer release later.	USD 330,000 Exact value Exact value: 330000 USD 2016-01-01 – 2016-12-31: 330000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Orexigen Therapeutics, Inc. · 2016-12-31 Orexigen Therapeutics, Inc. (edgar:1382911) Capital Expenditure: 330000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T14:56:07Z Snapshot: c8844721238a17150f5c7259969a0b0ffd22b7c31ea3be7bd20a59c5a5b16dc5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1382911/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 330000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1382911/000156459017005547/orex-20161231.xml#216293 Filing: 000156459017005547 The citation records this snapshot. The page link may show a newer release later.	−USD 110.04 million Calculation and evidence -109713000 − 330000 USD Exact free cash flow: -110043000 USD 2016-01-01 – 2016-12-31: -109713000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 330000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Orexigen Therapeutics, Inc. · 2016-12-31 Orexigen Therapeutics, Inc. (edgar:1382911) Free cash flow: -110043000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T14:56:07Z Snapshot: c8844721238a17150f5c7259969a0b0ffd22b7c31ea3be7bd20a59c5a5b16dc5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1382911?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -109713000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1382911/000156459017005547/orex-20161231.xml#213633 Filing: 000156459017005547 Input fundies:CapitalExpenditure: 330000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1382911/000156459017005547/orex-20161231.xml#216293 Filing: 000156459017005547 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

55 filings · 2,029 latest values · 2,029 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001382911, 1382911, OREX, edgar:1382911

Also known as Orexigen Therapeutics, Inc.

Orexigen Therapeutics, Inc.

Latest quarter

Revenue

Operating margin

Operating cash flow

Reported share-count change

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2016 2016-01-01 – 2016-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation